Perspectivas inmunoterapéuticas de la tuberculosis: Citocinas y «vacunas» de ADN

Revista Clinica Espanola

Volumn 200, Issue 6, 2000, Pages 318-322

  Leon Prieto F ^a   Arguelles Grande C ^b   Bootello Gil, A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital El Escorial de Madrid   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD8 ANTIGEN; CYTOKINE; DNA; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOTOXIN; MONOCLONAL ANTIBODY; RESIQUIMOD; VACCINE; DNA VACCINE;

HELPER CELL; HUMAN; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS; IMMUNOLOGY;

HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VACCINES, DNA;

EID: 0033869196     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(00)70645-X     Document Type: Review

References (87)

1. Perlman DC, Salomon N, Perkins MP, Yancovitz S, Paone D, Des Jarlais DC Tuberculosis in drug users Clin Infect Dis 1995; 21.1.253-1.264
2. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic JAMA 1995, 273, 220-226.
3. Cohn DL, Bustreo F, Raviglione MC Drug-resistant tuberculosis, review of the worlwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997, 24: S121-S130.
4. Moore M, Onorato IM, McCray E, Castro KG Trends in Drug-Resistant Tuberculosis in the United States, 1993-1996. JAMA 1997, 278.833-837
5. WHO Report on the Tuberculosis Epidemic 1996 Organización Mundial de la Salud, Ginebra, 1996.
6. Sudre P, Ten Darn G, Kochi A. Tuberculosis, a global overview of the situation today Bull World Health Organ 1992; 70.149-159.
7. Shinnick TM, ed. Tuberculosis. Curr Topics Microbiol Immunol 215. Berlin Springer-Verlag, 1996.
8. Koch R Weitere Mitteilungen uber ein heilmittel gegen tuberculose Dtsch Med Wschr 1891, 17.101-102
9. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more Immunol Today 1996; 17:138-146.
10. Heufler C, Koch F, Stanzl-U, et al Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26:659-668.
11. Takeda K, Tsutsui H, Yoshimoto T, et al Defective NK cell activity and Th1 response in IL-18-defective mice Immunity 1998, 8:383-390.
12. Barnes PF, Modlin RL. Human cellular immune responses to Mycobacterium tuberculosis. En Shinnick TM, ed. Tuberculosis. Curr Topics Microbiol Immunol 215. Berlin: Springer-Verlag, 1996;197-219.
13. Zhang M, Gately MK, Wang E, et al. Interleukin-12 at the site of disease in tuberculosis. J Clin Invest 1994; 93:1.733-1.739.
14. Orme IM. Immune responses in animal models. En. Shinnick TM, ed. Tuberculosis. Curr Topics Microbiol Immunol 215. Berlin: Springer-Verlag, 1996, 170-196.
15. Rooney JJ, Crocco JA, Kramer S, Lyons HA Further observations on tuberculin reactions in tuberculosis. Am J Med 1976; 60:517-522.
16. Trinchieri G. Interleukin-12. A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84 4.008-4.027
17. Hsieh C-S, Macatonia SE, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages Science 1993; 260:547-549.
18. Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS. Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol 1997; 84:185-193.
19. Boom WH, Chervenak KA, Mincek MA, Ellner JJ Role of the mononuclear phagocyte as an antigen-presenting cell for human T cells activated by live Mycobacterium tuberculosis. Infect Immun 1992; 60:3.480-3.488.
20. Sieling PA, Wang X-H, Gately MK, et al. Interleukin-12 regulates T-helper type 1 cytokine responses in human infectious disease. J Immunol 1994; 153.3.639-3.647.
21. Fulton SA, Johnsen JM, Wolf SF, Sieburth DS, Boom WH. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis Infect Immun 1996, 64:2 523-2 531.
22. Thompson-Snipes L, Skamene E, Radzioch D Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guerin is compromised by interleukin-12 ablation. Infect Immun 1998; 66:5.268-5.274.
23. Chehimi J, Starr SE, Frank I, et al. Impaired Interleukin-12 production in human immunodeficiency virus-infected patients J Exp Med 1994, 179:1 361-1.370.
24. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis J Exp Med 1997; 186.39-45.
25. Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL. Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-γ and IL-4 knockout mice. Analysis of local and regional cytokine and chemokine networks. J Immunol 1997, 159 3 565-3.573.
26. Cooper AM, Roberts AD, Rhoades ER, Callaham JE, Getzy DM, Orme IM. The role of IL-12 in immunity to Mycobacterium tuberculosis. Immunology 1995; 84:423-432.
27. Clenci M, Lucey DR, Berzovsky JA, et al Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993; 262 1 721-1.724.
28. Marshall JD, Secrist H, DeKruyff RH, Wolf SF, Umetsu DT IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes. J Immunol 1995, 155.111-117
29. Kim JJ, Ayyavoo V, Bagarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997, 158:816-823.
30. Rempel JD, Wang MD, HayGlass KT. In vivo IL-12 administration induces profound but transient commitment to T helper type 1-associated patterns of cytokine and antibody production J Immunol 1997. 159: 1 490-1 496.
31. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8.275-283
32. Mannaro M, Boyaka PN, Finkelman FD, et al. Oral but not parenteral IL-12 redirects T helper 2 responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997; 185:415-423.
33. Finkelman FD, Madden KB, Cheever AW, et al. Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 1994, 179 1 563-1 572.
34. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997; 90 2 541-2 548
35. Sacco S, Heremans H, Echtenacher B, et al. Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice role of cytokines and glucocorticoids. Blood 1997; 90: 4 473-4.479.
36. de Jong R, Janson AAM, Faber WR, Naafs B, Ottenhoff THM IL-2 and IL-12 act in synergy to overcome antigen-specific T cell unresponsiveness in mycobaterial disease J Immunol 1997; 159:786-793.
37. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98:1 676-1.683.
38. Johnson BJ, Bekker LG, Rickman R, et al. RhuIL-2 adjunctive therapy in multidrug resistant tuberculosis, a comparison of two treatment regimens and placebo Tuber Lung Dis 1997, 78:195-203
39. Johnson BJ, Ress SR, Willcox P, et al Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokine Mol Ther 1995, 1:185-196.
40. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 1997; 349: 1.513-1 515
41. Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123; 216-224.
42. Rook GAW, Hernández-Pando R. The pathogenesis of tuberculosis. Annu Rev Microbiol 1996; 50.259-284.
43. Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD, Tan PLJ. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997; 65:4.525-4.530.
44. Onyebujoh PC, Abdulmimini T, Robinson S, Rook GAW, Stanford JL. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Resp Med 1995; 89:199-207
45. Corlan E, Marica C, Macarei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1 Newly-diagnosed pulmonary disease. Resp Med 1997; 91:13-19.
46. Corlan E, Marica C, Macarei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease Resp Med 1997; 91:21-29.
47. Stanford JL, Grange JM. The promise of immunotherapy for tuberculosis. Resp Med 1994; 88:3-7.
48. Stanford JL, Stanford CA. Immunotherapy for tuberculosis with Mycobacterium vaccae. J Med Microbiol 1996; 44:24-34.
49. Grange JM Immunotherapy: a new strategy for tuberculosis control? Resp Med 1997, 91:1-4.
50. Marsh BJ, Von Reyn CF, Arbeit RD, Morin P. Immunization of HIV-infected adults with a three-dose series of inactive Mycobacterium vaccae. Am J Med Sci 1997; 313:377-383.
51. Kon OM, Goyal M, Filley E, et al Mycobacterium vaccae: a study of safety and outcome measures Respir Med 1998; 92: 597-598.
52. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial Durban Immunotherapy Trial Group. Lancet 1999; 354:116-119.
53. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2:540-544.
54. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization Proc Natl Acad Sci USA 1996; 93:5 141-5 145.
55. Yoshimoto T, Okamura H, Tagawa Y, Iwakura Y, Nakanish K Interleukin 18 together with interteukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 1997; 94 3.948-3 953
56. Leclerc C, Dériaud E, Rojas M, Whalen RG, The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA Cell Immunol 1997; 179:97-106
57. Pisetsky DS. Immunostimulatory DNA: A clear and present danger? Nat Med 1997, 3:829-831.
58. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186 1.623-1 631
59. Spiegelberg HL, Orozco EM, Roman M, Raz E DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy 1997; 52: 964-970
60. Zimmermann S, Egeter O, Hausmann S, et al Cutting Edge: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998, 160:3 627-3.630.
61. Lim YS, Kang BY, Kim EJ, Kim SH, Hwang SY, Kim TS Potentiation of antigen-specific. Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-γ hybrid construct. Immunology 1998; 94: 135-141.
62. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2:983-988.
63. Denis O, Tanghe A, Palfliet K, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by H37RV infection. Infect Immun 1998; 66:1.527-1.533.
64. Zhu X, Venkataprasad N, Ivanyi J, Vordermeier HM. Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection. Immunology 1997, 92:6-9
65. Chartergoon M, Boyer J, Weiner DB. Genetic immunization, a new era in vaccines and immune therapeutics FASEB J 1997; 11:753-763.
66. Li Z, Howard A, Kelley C, Delogu G, Collins F. Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 1999, 67:4.780-4.786
67. Velaz-Faircloth M, Cobb AJ, Horstman AL, Henry SC, Frothingham R. Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein Infect Immun 1999; 67:4.243-4.250.
68. Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination Nature 1999; 400:269-271
69. Hirsch CS, Ellner JJ, Blinkhorn R, Tootsi Z. In vitro restoration of T-cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor β Proc Natl Acad Sci USA 1997; 94:3.926-3 931.
70. Hirsch CS, Hussain R, Toossi Z, Dawood G, Shahid F, Ellner JJ. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production Proc Natl Acad Sci USA 1996. 93 3 193-3 198.
71. Converse PJ, Esa AH. Nordihydroguaiaretic acid blocks IL-2-independent lymphocyte proliferation and enhances responses to PPD. Scand J Immunol 1996; 43:127-133.
72. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996, 14:1-27.
73. Constant SL, Bottomly K Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297-322.
74. Kumar V, Bhardwaj V, Soares L, Alexander J, Sette A, Sercaz E. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon-γ by T cells Proc Natl Acad Sci USA 1995; 92 9.510-9.514.
75. Pfeiffer C, Stein K, Southwood SHK, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995, 181:1.569-1.574
76. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995, 81:979.
77. Carballido JM, Aversa G, Kaltoft K, et al. Reversal of human allergic T helper 2 responses by engagement of Signaling Lymphocytic Activation Molecule J Immunol 1997, 158:4.316-4.321.
78. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor production and enhances weight gain in patients with pulmonary tuberculosis Mol Med 1995; 1.384-397.
79. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M tuberculosis infection. J Acquir Immune Defic Syndr 1996; 11:247-257.
80. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline in HIV-1-seropositive tuberculosis: a randomized controlled trial J Infect Dis 1996, 174 727-733
81. Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated Immune responses into Th1-dominated responses. J Immunol 1998; 161: 4 146-4.152.
82. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on the Type 2 but not Type 1 helper T cells. J Exp Med 1998, 187 787-794
83. Ahuja SS, Reddick RL, Sato N, et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999; 163:890-897.
84. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and Imiquimod Cell Immunol 1999, 191.10-19.
85. Probst P, Skeiky YAW, Steeves M, Gervassi A, Grabstein KH, Reed SG. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-α production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol 1997; 27:2 634-2.642.
86. Pottumarthy S, Morris AJ, Harrison AC, Wells VC Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol 1999, 37:3.229-3 232
87. Weir RE, Butlin CR, Neupane KD, Failbus SS, Dockrell HM Use of a whole blood assay to monitor the immune response to mycobacterial antigens in leprosy patients: a predictor for type 1 reaction onset? Lepr Rev 1998, 69:279-293.